WHO: good news – COVID-19 vaccine

WHO: good news – COVID-19 vaccine

Quarantine measures help slow the spread of coronavirus infection, but in order to stop the epidemic, it is very important to identify new cases and isolate those who have been in contact with the infected. As the head of the World Health Organization, Dr. Tedros Geybreyesus, emphasized, “you don’t have to wait for a vaccine to save lives.” Meanwhile, WHO officials today welcomed the announcement of successful trials of the COVID-19 vaccine.

COVID-19 Vaccine: Successful Trials

The scientific evidence for the successful completion of the first phase of a vaccine trial is published in the latest issue of the respected scientific journal The Lancet. Scientists report that, according to the results of the first phase of clinical trials, which involved more than a thousand people aged 18 to 55 years, the candidate vaccine does not cause serious side effects and leads to the formation of virus neutralizing antibodies and T cells that provide immune response to coronavirus. Re-administration of the vaccine further enhances this effect.

Dr Michael Ryan, Director of Emergencies at WHO, congratulated British scientists on the success. He said there are 23 more “budding vaccine candidates” in development, and the results of two studies, including the brainchild of scientists at Oxford University, have already been published in scientific journals. Dr. Ryan warned that this is only the first phase of testing, there is still a long way to go. “However, this is very good news,” he stressed.

Tracking everyone who came into contact with the infected

The head of WHO, Dr. Tedros Geybreyesus, noted that one of the most important tools in the fight against the pandemic remains the isolation of all who have come into contact with the infected. “This is important for every country, in every situation,” emphasized Dr. Tedros. “This helps prevent localized outbreaks before they start to grow.” Even countries where coronavirus infection has already spread widely can succeed in containing the epidemic, he said, if they manage to “break” it into separate outbreaks and extinguish each of them separately.

“By quickly responding to new cases and outbreaks, countries will be able to recover their economies and at the same time contain the spread of the virus,” added the head of WHO. He warned that contact tracing is a very important tool, but not the only one: comprehensive measures must be taken.
At the same time, according to him, to identify the infected and those with whom they were in contact, perhaps even in the most difficult conditions. He cited as an example the successful fight against Ebola in the Democratic Republic of the Congo, where armed conflict continues. There are no hopeless situations, Dr. Tedros is convinced. “We should try to speed up the development of vaccines, but at the same time use whatever means we can [to stop the infection],” he said.

Indigenous people suffer more than other populations

During a press conference on Monday, the head of WHO also expressed concern about the rapid spread of COVID-19 among indigenous peoples, in particular in Latin America, which continues to be one of the main epicenters of the pandemic. As of early July, about 70,000 indigenous people were infected there and 2,000 died from the disease. WHO is working with local authorities to protect this population from infection.

  • buy Disposable Coveralls EN 14126

    Buy Disposable Coveralls Standard EN 14126

    $15.00 $13.00
    5.00 out of 5 1 1 Buy Disposable Coveralls Standard EN 14126 Disposable Coveralls Standard EN 14126 (Type 5-B) – Protective clothing against infections Requirements for the characteristics and test methods of protective clothing against infections are regulated in DIN EN 14126. Protective clothing tested in accordance with DIN EN 14126 guarantees resistance to penetration of biologically contaminated liquids. The special requirements for clothing used to protect against infectious agents ensure that human skin is protected from potential contact with biological substances, which helps prevent the spread of germs. PERSONAL PROTECTIVE EQUIPMENT (PPE) DIRECTIVE 2016/425 (EU) Type 5 EN ISO 13982-1 Type 6 EN 13034 EN 1073-2 2003 EN 14126 2003 EN 1149-5 2003 DDP shipping to door 13
  • Buy 3M mask N95 8210

    Buy 3M N95 Mask 8210

    5.00 out of 5 1 1 Buy 3M N95 Mask 8210 3M Mask N95 8210 respirator for protection against dust microparticles. The respirator is designed to provide reliable respiratory protection with a minimum of 95% filtration efficiency against certain microparticles other than petroleum products. Application: Assembly, cleaning, dismantling, grinding, sandblasting, welding, construction, food processing, mining, pharmaceutical production. 4.55
  • Buy 3M N95 Mask

    Buy 3M N95 Mask 1860

    $6.25 $2.09
    5.00 out of 5 1 2 Buy 3M N95 Mask 1860 3M mask N95 1860 designed to be worn by medical personnel during surgical operations, protects the patient and medical workers from the transfer of microorganisms, biological fluids and particulate matter. Protects respiratory organs from biological particles carried by airborne droplets. 3M mask N95 is disposable and resistant to blood spatter and other infectious materials. N95 NIOSH Standard FDA approved for use as a surgical mask BFE (Bacterial Filtration Efficiency ) > 99% Protection class: FFP2 Made in USA DDP shipping to door 2.09
  • KN95 mask for sale

    Buy KN95 mask

    $1.95 $1.50
    5.00 out of 5 1 1 Buy KN95 mask KN95 mask disposable hygienic and easy-to-use. This respirator made of high quality materials, soft and comfortable. 95% filtration, provides antibacterial and dust protection class N95, FFP2. Protect you from suspended particles and contaminants. Elastic earloops and an adjustable nose clip for different face shapes and sizes. Ideal for daily use and outdoor activities. Europe standard: EN 149 2001 + A1: 2009 PFE (Nonoily particles filtration efficiency) > 95% BFE (Bacterial filtration efficiency) > 98% Protection class: N95, FFP2 DDP shipping to door 1.5

Leave a Reply

Select your currency
USD United States (US) dollar
EUR Euro